The erroneous ruling by the CAFC in the Lovenox patent case in Jan 2012—which had the temporary effect of rendering drug-manufacturing patents unenforceable—has finally been reversed. Had the Court’s 2012 ruling stood, it would have eventually wreaked havoc on the US drug/biotech industry.
>>NVS/MNTA’s suit against TEVA was dismissed, but the suit against AMPH (and its partner, AGN) continues.
If I'm reading this right the distinction the court drew is the TEVA product is made outside the US. That makes no sense at all in the big scheme of things.
This whole dispute has not been our patent dispute resolution's finest hour.
MNTA/Lovenox update from AMPH’s 3Q15 CC: AMPH is now boasting that it has “strong defenses” in the Lovenox patent trial that has been remanded to the US District Court (#msg-118404904); however, AMPH’s executives are no longer talking about collecting on NVS/MNTA’s $100M District Court bond that has been held by the Court since Oct 2011, pending a final outcome in the patent case.
Market Data 
Markets 
AI
